An observational study in Venous Thromboembolism, Abdominal Cancer Surgery and Pelvic Surgery, sponsored by University of Chicago. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Chicago · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 221 studies in Venous Thromboembolism with a site in United States — 37 open to participants now, 40 under way, 8 of them phase 3. Venous Thromboembolism · United States.
Among the 221 studies in Venous Thromboembolism with a site in United States, this one is the 46th largest by planned enrollment of the 56 observational ones that give a count, is one of 2 that started in 2027, is one of 56 observational ones, reaches primary completion later than 26 of the 39 other live ones, and was the 221st registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →37 of the 221 studies in Venous Thromboembolism with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18–80
Brigham and Women's Hospital · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Georgia, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
221 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 33 · Phase 3 50 · Phase 4 26
First in 2001; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 700 across 283 observational studies indexed under Venous Thromboembolism.
Median enrollment 218 across the 165 interventional studies, 1,094 across the 56 observational. Of the 163 that completed or were terminated, 79 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 221 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 1 study filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
19 of the studies in Venous Thromboembolism with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07015905Phase 3Regeneron PharmaceuticalsREGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | 2027-02-20 |
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT02832245Manuel MonrealComputerized Registry of Patients With Venous Thromboembolism (RIETE) | 2026-12 |
| NCT05683808University of Vermont Medical CenterVenous Thromboembolism Prevention in Outpatients With Glioma | 2026-12-30 |
Add all 19 to your calendar (.ics) → With an account.
Among the 221 studies in Venous Thromboembolism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Venous thromboembolism (VTE) is the most common preventable cause of death after major abdominal and pelvic cancer surgery, and over one-third of events occur after discharge. National guidelines recommend extended post-discharge chemoprophylaxis, but hospital adherence varies widely. This observational study has two parts. Aim 1 uses interviews, focus groups, and surveys with patients, clinicians, and health system stakeholders to identify barriers and facilitators to implementing a post-discharge VTE chemoprophylaxis quality improvement project. Aim 2 uses retrospective hospital- and population-level data and coincidence analysis to identify hospital performance phenotypes and develop targeted implementation strategies. Findings will inform a separately registered stepped-wedge implementation trial (Aim 3).
Aim 1: Semi-structured interviews, focus groups, and electronic surveys will be conducted with patients (n≈20) undergoing abdominal or pelvic cancer surgery, clinicians (n≈20), and health system stakeholders (n≈10). Surveys include study-specific VTE chemoprophylaxis and ordering surveys, the Organizational Readiness to Change Assessment (ORCA), and the Safety Attitudes Questionnaire (SAQ). Interviews are audio-recorded, transcribed, de-identified, and analyzed with hybrid inductive and deductive coding mapped to CFIR domains. Patient eligibility is screened through the medical record; screening data are not linked to survey or interview responses.
Aim 2: De-identified, retrospective hospital- and population-level data (demographics, procedure details, VTE prophylaxis orders, VTE outcomes), obtained through the University of Chicago Center for Research Informatics, will be analyzed using coincidence analysis (CNA) to identify causal pathways, define low- and high-performance hospital phenotypes, and develop targeted implementation strategies. Aim 2 data are kept separate from Aim 1 recruitment data.
This record covers Aims 1 and 2 only. The Aim 3 stepped-wedge trial is registered separately
Patients, clinicians, and health system stakeholders involved in abdominal and pelvic cancer surgery care, plus a retrospective hospital-level dataset.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aim 2: records of patients undergoing abdominal or pelvic cancer surgery between 1/1/2006 and 9/16/2025
Exclusion Criteria:
Adults undergoing abdominal or pelvic cancer surgery at the University of Chicago Medical Center, interviewed or surveyed about post-discharge VTE chemoprophylaxis.
Surgeons, advanced practice providers, nurses, and other clinical staff who care for abdominal and pelvic cancer surgery patients, interviewed or surveyed.
Chief Medical, Information (or Medical Information), and Quality Officers and related leadership, interviewed.
De-identified, hospital- and population-level records of abdominal and pelvic cancer surgery patients, 2006-2025
Barriers and facilitators to post-discharge VTE chemoprophylaxis implementation
Themes identified from interviews and focus groups, coded and mapped to CFIR domains
Time frame: Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
Organizational readiness to change (ORCA score)
Survey scores, dichotomized as low or high
Time frame: Year 1 and 2; Single survey at enrollment.
Safety and quality culture (SAQ score)
Survey scores, dichotomized as low or high.
Time frame: Year 1 and 2; Single survey at enrollment.
VTE chemoprophylaxis ordering patterns
Survey responses on type of prophylaxis prescribed, reasoning, and risk factors.
Time frame: Year 1 and 2; Single survey at enrollment.
Hospital performance phenotypes
Number and characteristics of low- and high-performance phenotypes identified by coincidence analysis of Aim 1 and retrospective data.
Time frame: Year 3; Following AIM 2 completion.
Plan to share: Undecided — Qualitative recordings and transcripts will not be shared. De-identified data will be retained in secure University of Chicago storage, and any external sharing would require IRB review
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.
Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 12 months is below that.
Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.